Incyte's (INCY, $85.97) clinical trial disappoints
Incyte Corporation shares took a hit late trading Thursday, after news of disappointing results on one of its clinical trials.
The pharmaceutical company revealed that one of its drugs fell short of meeting its primary endpoint in a phase 3 trial. According Incyte’s statement, its JAK1 inhibitor itacitinib in combination with corticosteroids, “did not statistically improve overall response rate or non-relapse mortality” in patients with acute graft-versus-host disease. That is, it did not meet the primary endpoint of a statistically significant improvement in overall response rate (ORR) at Day 28 compared to placebo plus corticosteroids; also, no difference was found in non-relapse mortality at month 6, which is a crucial secondary endpoint.
The above-mentioned disease is often seen in patients undergoing bone marrow or organ transplants. Results of the trial will be submitted at a future medical conference.
Incyte shares were down around -10% after hours.
INCY saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for INCY moved out of overbought territory on October 09, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 64 similar instances where the indicator exited the overbought zone. In of the 64 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 29, 2025. You may want to consider a long position or call options on INCY as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for INCY just turned positive on October 15, 2025. Looking at past instances where INCY's MACD turned positive, the stock continued to rise in of 34 cases over the following month. The odds of a continued upward trend are .
INCY moved above its 50-day moving average on October 13, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INCY advanced for three days, in of 307 cases, the price rose further within the following month. The odds of a continued upward trend are .
INCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 228 cases where INCY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. INCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.034) is normal, around the industry mean (24.092). P/E Ratio (20.371) is within average values for comparable stocks, (54.529). Projected Growth (PEG Ratio) (0.125) is also within normal values, averaging (2.181). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (3.743) is also within normal values, averaging (350.392).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of drugs
Industry Biotechnology
Advertisement